LFB (Laboratoire Français du Fractionnement et des Biotechnologies)

What LFB (Laboratoire Français du Fractionnement et des Biotechnologies) does

LFB (Laboratoire Français du Fractionnement et des Biotechnologies) is a French biopharmaceutical company founded in 1994 that develops, manufactures, and commercialises plasma-derived biomedicines for the treatment of serious and rare diseases. The company produces approximately fifteen biomedicines addressing bleeding and coagulation disorders (hemophilia A and B, von Willebrand disease, rare factor deficiencies), immune deficiencies (human normal intravenous immunoglobulins), and other rare pathologies. Its core technology is plasma fractionation: the company collects plasma and transforms it into medicinal products through proprietary bioproduction techniques spanning both plasma-derived and recombinant protein platforms. Operations are structured through three core divisions — LFB BIOMEDICAMENTS (commercialisation), LFB BIOMANUFACTURING (production), and LFB BIOTECHNOLOGIES (clinical and medical affairs) — supported by LFB GLOBAL PLASMA for plasma sourcing.

LFB operates five production sites in France (Alès, Arras, Carvin, Les Ulis, Lille), with the newly commissioned Arras plant enabling a tripling of plasma-derived production capacity. The company generated €599.6 million in revenue in 2024 with a global workforce of 3,086. Distribution occurs through wholly-owned subsidiaries in the UK, Germany, Belgium, Spain, the United States, and Mexico, complemented by distribution partners across 16+ European countries plus Colombia, UAE, Hong Kong, India, Kuwait, Lebanon, Morocco, Tunisia, and Turkey. Customers are hospitals, blood transfusion centers, and healthcare professionals; the go-to-market is B2B enterprise field sales with reimbursement routed through national health systems.

The company positions itself as a pillar of French health sovereignty, supplying essential medicines often unavailable from other sources for rare disease patients. Strategic priorities include international expansion, bioprocess platform modernisation (notably the Sartorius partnership), and incremental indication extension (e.g., the Arthritis4Cure collaboration on rheumatoid arthritis immunotherapy). Awards include a 98/100 Gender Equality Index score (2024) and TOP 10 ranking in France for work-linked training (2026).

Name

LFB (Laboratoire Français du Fractionnement et des Biotechnologies)

Legal name

Laboratoire français du Fractionnement et des Biotechnologies (LFB SA)

Website

https://groupe-lfb.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

LFB is a French biopharmaceutical company that develops, manufactures, and commercialises approximately fifteen plasma-derived biomedicines for rare bleeding/coagulation disorders and immune deficiencies, selling to hospitals and healthcare institutions across 29+ countries via five French production sites and international subsidiaries.

Ownership category

akta.pro rank

Product category

Plasma-derived biopharmaceuticals for rare diseases

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Plasma Fractionation & Purification Manufacturing (HLAIAHAI)

akta.pro secondary industries

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Plasma-Derived Coagulation Factors (Hemophilia Therapies) (HLAIAHAB), Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Plasma-derived medicines
• Biopharmaceutical manufacturing
• Rare disease treatments
• Immunoglobulin therapies
• Coagulation factor products

Headquarters

HQ city

Courceboeufs

HQ country

France

HQ region

Europe

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Biomedicines Sales: LFB develops, manufactures, and commercializes biomedicines derived from plasma for the treatment of rare diseases, bleeding disorders, and immune deficiencies. Revenue is generated through the sale of approximately fifteen biomedicinal products to hospitals, healthcare facilities, and through international distribution channels.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

LFB develops, manufactures, and commercializes plasma-derived biomedicines for the treatment of rare and serious diseases, producing approximately fifteen biomedicines from human plasma through industrial-scale fractionation. Its products target rare bleeding and coagulation disorders (hemophilia A and B, von Willebrand disease, rare coagulation factor deficiencies) and immune deficiencies (primary immunodeficiencies and immune-mediated neuropathies) treated with human normal intravenous immunoglobulins. The company also operates LFB Biomanufacturing as a contract manufacturing organization for biopharmaceutical production.

Product overview

LFB (Laboratoire Français du Fractionnement et des Biotechnologies) is a French biopharmaceutical company specializing in plasma-derived biomedicines. The company operates through three main divisions: LFB BIOMEDICAMENTS (core product development and commercialization), LFB BIOMANUFACTURING (production operations), and LFB BIOTECHNOLOGIES (clinical research). Together they produce approximately fifteen biomedicines for rare diseases, primarily targeting coagulation disorders (hemophilia, von Willebrand disease) and immunological conditions. The company has 3,086 employees worldwide and generated €599.6 million in revenue in 2024, with production sites across France including Les Ulis, Lille, Carvin, Arras, and Alès.

Differentiator

Problem solved

Functional benefit

Products and services

• Plasma-derived biomedicines portfolio (LFB Biomedicaments) A portfolio of approximately fifteen plasma-derived biomedicines developed, manufactured, and commercialized by LFB Biomedicaments to treat rare diseases, including coagulation factor concentrates for hemophilia A and B, von Willebrand disease and rare coagulation factor deficiencies, and human normal intravenous immunoglobulins for primary immunodeficiencies and immune-mediated neuropathies. Sold to hospitals, blood transfusion centers, and healthcare providers.
• Contract biomanufacturing services (LFB Biomanufacturing) Contract manufacturing services for biopharmaceuticals offered by LFB Biomanufacturing, leveraging bioproduction capacity at the Alès site and partnerships with bioprocessing specialists such as Sartorius. Includes co-development of plasma-derived and recombinant products with biotech partners such as Arthritis4Cure for targeted immunotherapies.
• Clinical and medical affairs research (LFB Biotechnologies) Clinical and medical affairs research services conducted by LFB Biotechnologies, including real-world patient registry studies such as the PIDC (Chronic Inflammatory Demyelinating Polyneuropathy) study using BNDMR and SNDS health data, with CNIL authorization (N°924112) and BNDMR scientific committee approval.

Quantifiable outcome

• New Arras plant enables tripling of production capacity for plasma-derived medicinal products
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature2 records

Partnerships

Four partnerships are on record, tiered core and minor.

• SartoriuscoreStrategic or Co-development Partner · 23 June 2026Sartorius and LFB BIOMANUFACTURING have strengthened their collaboration, likely in the area of biomanufacturing equipment and processes for production of plasma-derived medicinal products.
• Healthcare professionals and research institutionsminorStrategic or Co-development Partner · 10 March 2026LFB Immunology Research Grant program supports healthcare professionals conducting research in immunodeficiency and immune-mediated neuropathies in 11 countries (Austria, Belgium, France, Germany, Greece, Italy, Mexico, Spain, Netherlands, Turkey, United Kingdom).
• Guerbet, Ipsen, Pierre Fabre, Sanofi, Servier, ThéacoreStrategic or Co-development Partner · 8 January 2026LFB along with major French pharmaceutical companies announced the creation of a new professional union focused on innovation and French health sovereignty.
• Arthritis4CureminorStrategic or Co-development Partner · 6 March 2025Arthritis4Cure and LFB BIOMANUFACTURING joined forces to accelerate the development and production of a targeted immunotherapy against rheumatoid arthritis.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Market position

Strengths4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/SocieteLFB
• LinkedInlinkedin.com/company/lfb
• Xx.com/groupe_lfb

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries10 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LFB (Laboratoire Français du Fractionnement et des Biotechnologies)